Cell Genesys has ended the trial of its prostate cancer candidate, GVAX. In a critical Phase III trial, patients receiving GVAX had slightly higher death rates than those receiving chemotherapy.
It is worth stating that like nearly all other cancer vaccine trials, the patients enrolled in the trial are the sickest of the sickest…those with metastatic disease that have failed other therapies.
Cancer vaccines been plagued by problems. Last year, the FDA torpedoed the hopes of many men with prostate cancer by failing to approve Dendreon’s Provenge (against the recommendation of nearly everyone, including its own advisory committee).